Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sands

Showing results (121-130 of 513) with videos related to

Pageof 52
Sort By:
The American Journal of Gastroenterology|June 18, 2003
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochlorideDavid P Miller, Tanya Alfredson, Suzanne F Cook, et al.
Inflammatory Bowel Diseases|January 25, 2012
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?Ashwin D Dhanda, Tom J Creed, Rosemary Greenwood, et al.
Infection Control and Hospital Epidemiology|May 30, 1998
Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of useM V Singer, R Haft, T Barlam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed SolutionsPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2006
Risks and benefits of infliximab for the treatment of Crohn's diseaseCorey A Siegel, Chin Hur, Joshua R Korzenik, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 19, 2008
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complicationsHiroko Kunitake, Richard Hodin, Paul C Shellito, et al.
Journal of Clinical Gastroenterology|December 24, 2016
There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral CenterShailja C Shah, Steven Naymagon, Benjamin L Cohen, et al.
Scandinavian Journal of Gastroenterology|April 14, 2015
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factorsAndrew Tinsley, Steven Naymagon, Bradley Mathers, et al.
Inflammatory Bowel Diseases|March 7, 2024
Dietary Interventions and Supplementation in Patients With an Ileal Pouch-Anal Anastomosis: A Systematic ReviewStephanie Gold, Carrie Levinson, Jean-Frederic Colombel, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter speciesMitchell J Schwaber, Camilla S Graham, Bruce E Sands, et al.
Pageof 52

Showing results (121-130 of 513) with videos related to

Sort By:
Pageof 52
The American Journal of Gastroenterology|June 18, 2003
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochlorideDavid P Miller, Tanya Alfredson, Suzanne F Cook, et al.
Inflammatory Bowel Diseases|January 25, 2012
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?Ashwin D Dhanda, Tom J Creed, Rosemary Greenwood, et al.
Infection Control and Hospital Epidemiology|May 30, 1998
Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of useM V Singer, R Haft, T Barlam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed SolutionsPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2006
Risks and benefits of infliximab for the treatment of Crohn's diseaseCorey A Siegel, Chin Hur, Joshua R Korzenik, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 19, 2008
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complicationsHiroko Kunitake, Richard Hodin, Paul C Shellito, et al.
Journal of Clinical Gastroenterology|December 24, 2016
There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral CenterShailja C Shah, Steven Naymagon, Benjamin L Cohen, et al.
Scandinavian Journal of Gastroenterology|April 14, 2015
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factorsAndrew Tinsley, Steven Naymagon, Bradley Mathers, et al.
Inflammatory Bowel Diseases|March 7, 2024
Dietary Interventions and Supplementation in Patients With an Ileal Pouch-Anal Anastomosis: A Systematic ReviewStephanie Gold, Carrie Levinson, Jean-Frederic Colombel, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter speciesMitchell J Schwaber, Camilla S Graham, Bruce E Sands, et al.
Pageof 52